Business
MedX Announces Non-Brokered Private Placement of Series IV Convertible Loan Notes
MISSISSAUGA, Ontario, February 02, 2026--MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) is pleased to announce that it is proposing a non-brokered Private Placement to accredited investors of up to $5 million by issuance of up to 100 Convertible Loan Notes, each with a face value of $50,000 ("Series IV Notes"). The Series IV Notes will bear interest at 6% per year, payable Quarterly, and will mature on December 31, 2028 (the "Maturity Date"). The Series IV Notes may be converted, at th
About this update from Medx Health Corp.
MISSISSAUGA, Ontario, February 02, 2026--(BUSINESS WIRE)--MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) is pleased to announce that it is proposing a non-brokered Private Placement to accredited investors of up to $5 million by issuance of up to 100 Convertible Loan Notes, each with a face value of $50,000 ("Series IV Notes"). The Series IV Notes will bear interest at 6% per year, payable Quarterly, and will mature on December 31, 2028 (the "Maturity Date"). The Series IV Notes may be converted, at the option of the Holder, into units at $0.10 per unit ("Unit") at any time until the Maturity Date. Each Unit will be comprised of One (1) fully paid Common Share and One-half (1/2) of a Share Purchase Warrant. Each whole Share Purchase Warrant will be exercisable to purchase One (1) further Common Share at the price of $0.125, exercisable for a period expiring on the Maturity Date. Closing of the Placement, which is subject to a minimum subscription of $2.65 million, will be subject to receipt of subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Holders of Series I Convertible Loan Notes ("Series I Notes") who wish to do so, will be able to surrender their Series I Notes by way of subscription for Series IV Notes. It is anticipated that, subject to compliance with relevant regulatory provisions, certain Insiders will participate in this Placement, in which case the Company will rely on exemptions from formal valuation and minority shareholder approval requirements set out in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions. Qualified agents will receive a cash commission equal to 6% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s) and agent’s warrants ("Agent’s Warrant(s)") equal to 6% of subscriptions introduced by such agent(s). Each Agent’s Warrant, which will be non-transferable, will entitle the holder to acquire, at the price of CAD$0.10, a unit, comprised of One (1) fully paid Common Share and one-half (1/2) of a non-transferable agent’s share purchase warrant; each whole agent’s share purchase warrant ("Agent’s Share Purchase Warrant"), wil...